Código QR (código de barras bidimensional)

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort

Introduction: The treatment landscape of metastatic renal cell carcinoma has advanced significantly with the approval of combination regimens containing an immune checkpoint inhibitor (ICI) for patients with treatment-naïve disease. Little information is available regarding the activity of single-ag...

ver descrição completa

Na minha lista:
Principais autores: Pedro Barata, Whitley Hatton, Arpita Desai, Vadim Koshkin, Ellen Jaeger, Charlotte Manogue, Patrick Cotogno, Malcolm Light, Brian Lewis, Jodi Layton, Oliver Sartor, Arnab Basu, Deepak Kilari, Hamid Emamekhoo, Mehmet A. Bilen
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020-10-01
coleção:Frontiers in Oncology
Assuntos:
metastatic renal cell carcinoma
immunotherapy
PD-1/PD-L1 inhibitor
monotherapy
first-line treatment
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2020.581189/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados